Systemic Modulation of Lymphocyte Subsets Using siRNAs Delivered via Targeted Lipid Nanoparticles

  • Inbal Hazan-Halevy
  • Daniel Rosenblum
  • Srinivas Ramishetti
  • Dan PeerEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1974)


Systemic delivery of RNA interference (RNAi) payloads for manipulation of gene expression in lymphocytes holds a great potential as a novel therapeutic modality for hematological malignancies and autoimmune disorders. However, lymphocytes are among the most difficult cells to transfect with RNAi, as they are resistant to conventional transfection reagents and are dispersed throughout the body, making it a challenge to successfully deliver these payloads via systemic administration route. We have developed a strategy to target lymphocytes and deliver RNAi payloads in a cell-specific manner to induce therapeutic gene silencing. This approach utilizes antibodies that decorate lipid nanoparticle surfaces to home into lymphocyte subsets. This approach opens new avenues for discovery of new drug targets and potentially for therapeutics.


RNA interference (RNAi) Gene silencing Small interfering RNAs (siRNAs) Lipid nanoparticles (LNPs) 



This work was supported in part by grants from the Dotan Hemato-oncology Center at Tel Aviv University, by the Lewis Trust for blood cancers and by the Leona M. and Harry B. Helmsley Nanotechnology Research Fund awarded to D.P.


  1. 1.
    Coelho T, Adams D, Silva A et al (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369:819–829CrossRefPubMedGoogle Scholar
  2. 2.
    Tabernero J, Shapiro GI, LoRusso PM et al (2013) First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3:406–417CrossRefPubMedGoogle Scholar
  3. 3.
    Peer D, Karp JM, Hong S et al (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760CrossRefGoogle Scholar
  4. 4.
    Rietwyk S, Peer D (2017) Next-generation lipids in RNA interference therapeutics. ACS Nano 11:7572–7586CrossRefPubMedGoogle Scholar
  5. 5.
    Leung AK, Tam YY, Chen S et al (2015) Microfluidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems. J Phys Chem B 119:8698–8706CrossRefPubMedGoogle Scholar
  6. 6.
    Mizrahy S, Hazan-Halevy I, Dammes N et al (2017) Current progress in non-viral RNAi-based delivery strategies to lymphocytes. Mol Ther 25:1491–1500CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ramishetti S, Landesman-Milo D, Peer D (2016) Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles. J Drug Target 24:1–7CrossRefGoogle Scholar
  8. 8.
    Akinc A, Querbes W, De S et al (2010) Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18:1357–1364CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Novobrantseva TI, Borodovsky A, Wong J et al (2012) Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells. Mol Ther Nucleic Acids 1:e4CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Morrissey DV, Lockridge JA, Shaw L et al (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23:1002–1007CrossRefPubMedGoogle Scholar
  11. 11.
    Ramishetti S, Kedmi R, Goldsmith M et al (2015) Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles. ACS Nano 9:6706–6016CrossRefPubMedGoogle Scholar
  12. 12.
    Weinstein S, Toker IA, Emmanuel R et al (2016) Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc Natl Acad Sci U S A 113:E16–E22CrossRefPubMedGoogle Scholar
  13. 13.
    Weinstein S, Emmanuel R, Jacobi AM et al (2012) RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma. PLoS One 7:e43343CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Jayaraman M, Ansell SM, Mui BL et al (2012) Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angewandte Chemie 51:8529–8533CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Inbal Hazan-Halevy
    • 1
    • 2
    • 3
    • 4
  • Daniel Rosenblum
    • 1
    • 2
    • 3
    • 4
  • Srinivas Ramishetti
    • 1
    • 2
    • 3
    • 4
  • Dan Peer
    • 1
    • 2
    • 3
    • 4
    • 5
    Email author
  1. 1.Laboratory of Precision NanoMedicine, School of Molecular Cell Biology and BiotechnologyTel Aviv UniversityTel AvivIsrael
  2. 2.Department of Cell Research and Immunology, George S. Wise Faculty of Life SciencesTel Aviv UniversityTel AvivIsrael
  3. 3.Center for Nanoscience and NanotechnologyTel Aviv UniversityTel AvivIsrael
  4. 4.Cancer Biology Research CenterTel Aviv UniversityTel AvivIsrael
  5. 5.Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of EngineeringTel Aviv UniversityTel AvivIsrael

Personalised recommendations